Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Post-ASH 2024 MDS Highlights
28 January 2025 | Virtual Webinar
Post-ASH 2024 MDS Highlights
Featuring presentations & discussions on selected MDS abstracts from the 66th ASH Annual Meeting and Exposition
Tuesday 28 January | 08:00 – 10:00 CST/ 14:00 – 16:00 GMT/ 15:00 – 17:00 CET
Chair: Amer Zeidan | Moderators: Uwe Platzbecker and Valeria Santini
The Post-ASH 2024 MDS Highlights was supported by Genentech and Bristol Myers Squibb. Supporters have no influence over the production if the content.
Explore all presentations and discussions below:
Session 1: Risk stratification and classification
Prognostic Value of the MRD in AML Treatment with Venetoclax in Combination with Hypomethylating Agents: Validation of the ELN 2021 MRD Recommendations
Carlos Jimenez-Vicente Hospital Clinic Barcelona, Barcelona, Spain
Newly Developed Prognostic Score for MDS with Isolated 5q Deletion
Maria Julia Montoro Vall d’Hebron University Hospital, Barcelona, Spain
High-Risk CCUS Is Clinically Indistinguishable from Low-Risk Myelodysplastic Syndromes/Neoplasms
Zhuoer Xie Moffitt Cancer Center, Rochester, MN, United States
Panel Discussion
Session 2: Managing anemia in MDS
Early Versus Late Onset of ESA in Lower Risk Anemic MDS Patients: Results of the GFM Randomized Phase III EPO-Pretar Trial
Sophie Park CHU Grenoble Alpes, Grenoble, France
Long-Term Response Analysis of Transfusion Independence in Erythropoiesis Stimulating Agent-Naïve Patients with Very Low-, Low-, or Intermediate-Risk MDS Treated with Luspatercept Vs Epoetin Alfa in the COMMANDS Trial
Guillermo Garcia-Manero University of Texas MD Anderson Cancer Center, Houston, TX, United States
Combining ESA and Luspatercept in Non-RS MDS Patients Having Failed ESA – Results of the Phase I/II Part a of the GFM Combola Study
Lionel Ades Saint-Louis Hospital, Paris, France
Effect of Prior Treatments on the Clinical Activity of Imetelstat in Transfusion-Dependent Patients with ESA, Relapsed or Refractory/Ineligible Lower-Risk MDS
Uwe Platzbecker University Hospital Carl Gustav Carus, Dresden, Germany
A Phase II Study Evaluating the Efficacy and Safety of Imetelstat in Patients with Advanced Myelodysplastic Neoplasms or AML Failing HMA-Based Therapy – Interim Analysis Results of the Impress Study
Uwe Platzbecker University Hospital Carl Gustav Carus, Dresden, Germany
Panel Discussion
Session 3: Novel therapies and treatment options
Results from a Phase I Open-Label Dose Escalation and Expansion Trial of Oral Azacitidine + Cedazuridine (ASTX030) in Patients with MDS and MDS/Myeloproliferative Neoplasms (MPN)
Guillermo Garcia-Manero University of Texas MD Anderson Cancer Center, Houston, TX, United States
Oral Decitabine/Cedazuridine in Patients with MDS and TP53 Mutations: A Propensity Score Matching Analysis from the Phase II and III Trials
Samuel Urrutia Washington University School of Medicine, St. Louis, MO, United States
Updated Results from a Phase II Study of Vibecotamab, a CD3-CD123 Bispecific T-Cell Engaging Antibody, for MDS or CMML after Hypomethylating Failure and in MRD-Positive AML
Nicholas Short The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Preliminary Safety and Biomarker Results of the NLRP3 Inflammasome Inhibitor DFV890 in Adult Patients with Myeloid Diseases: A Phase Ib Study
Guillermo Garcia-Manero University of Texas MD Anderson Cancer Center, Houston, TX, United States
Preliminary Safety, Efficacy and Molecular Characterization in Patients with Higher-Risk MDS Treated with Single Agent Emavusertib
Guillermo Garcia-Manero University of Texas MD Anderson Cancer Center, Houston, TX, United States
Panel Discussion
